Molecular basis for LDL receptor recognition by PCSK9.

Area of Science:

• Structural Biology
• Molecular Medicine
• Biochemistry

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates hepatic low-density lipoprotein receptors (LDLRs), impacting LDL-cholesterol levels.
• PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of LDLR, targeting it for degradation.
• Understanding this interaction is key to developing therapies for hypercholesterolemia.

Purpose of the Study:

• To determine the crystal structure of the PCSK9-LDLR EGF-A domain complex.
• To identify the precise binding site and key residues involved in the PCSK9-LDLR interaction.
• To explore potential therapeutic strategies for modulating PCSK9 activity.

Main Methods:

• Crystallography was used to obtain the high-resolution structure of the PCSK9-LDLR EGF-A complex.
• Analysis of the crystal structure identified the binding interface on PCSK9 and its interaction with the LDLR EGF-A domain.
• Site-directed mutagenesis was employed to investigate the role of specific PCSK9 residues in LDLR binding.

Main Results:

• The crystal structure reveals that the LDLR EGF-A domain binds to the surface of PCSK9's subtilisin-like catalytic domain, away from the catalytic site.
• Key residues, including Arg-194 and Phe-379 on PCSK9, are critical for high-affinity binding to the LDLR's extracellular domain.
• A gain-of-function mutation (Asp-374-Tyr) was observed to increase PCSK9 affinity for LDLR, correlating with higher plasma LDL-cholesterol.

Conclusions:

• The determined structure elucidates the molecular basis of PCSK9-LDLR interaction.
• The identified binding interface provides a target for developing novel therapeutic agents.
• Interfering with this interaction could enhance LDLR function and reduce plasma LDL-cholesterol levels.